Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Xuejun Chen, Xiang Liu, Phillip Wang, Swamy Yeleswaram, PhD

Blood (2019) 134 (Supplement_1): 4534.

https://doi.org/10.1182/blood-2019-124027

Published: 2019

Journal Articles

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Indeg Sly, Niall James Davison

Blood (2019) 134 (Supplement_1): 3457.

https://doi.org/10.1182/blood-2019-122904

Published: 2019

Journal Articles

Leukemic Transformation of Post-Essential Thrombocythemia Myelofibrosis: A Unique Case Presenting with Double MPL and CALR Mutations

Cédric Cleyrat, PhD, Devon S Chabot-Richards, MD, David T Lynch, MD, Jason Gotlib, MD, Tracy I. George, Bridget S. Wilson, PhD, Mohammad A Vasef, MD, Cecilia Arana-Yi, MD

Blood (2017) 130 (Supplement 1): 4215.

https://doi.org/10.1182/blood.V130.Suppl_1.4215.4215

Published: 2017

Journal Articles

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Ellen K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, Richard T Silver, MD, Andrew I Schafer, MD, Joseph Scandura, MDPhD, Pinkal Desai, MD MPH, Sangmin Lee, MD, Michael Samuel, MD

Blood (2017) 130 (Supplement 1): 2910.

https://doi.org/10.1182/blood.V130.Suppl_1.2910.2910

Published: 2017

Journal Articles

Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood . 2013;122(25): 4047-4053 .

Blood (2016) 128 (25): 3013.

https://doi.org/10.1182/blood-2016-11-750505

Published: 2016

Journal Articles

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ronald Paquette, MD, Jason R. Gotlib, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Peter Langmuir, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3118.

https://doi.org/10.1182/blood.V128.22.3118.3118

Published: 2016

Journal Articles

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Sandra Malak, MD, Pascale Cony-Makhoul, MD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Philippe Rodon, MD, Fabienne Vacheret, MD, Barraco Fiorenza, MD, Francoise Boyer, MD, Katell Le Du, MD, Loic Garcon, MD PhD, Francois Lefrere, MD, Mathieu Wemeau, MD, Valerie Ugo, MD PhD, Jean-Jacques Kiladjian, MD PhD, Lydia Roy, MD

Blood (2016) 128 (22): 3123.

https://doi.org/10.1182/blood.V128.22.3123.3123

Published: 2016

Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison

Blood (2016) 128 (22): 3131.

https://doi.org/10.1182/blood.V128.22.3131.3131

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3110.

https://doi.org/10.1182/blood.V128.22.3110.3110

Published: 2016

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Elizabeth O. Hexner, MD, Haifa Kathrin Al-Ali, MD, Lynda Foltz, MD FRCP, Michael Montgomery, MD, Wei Peng, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Hagop Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 1604.

https://doi.org/10.1182/blood.V126.23.1604.1604

Published: 2015

Journal Articles

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Karolin Hubert, Mrs, Thoralf Lange, MD, Udo Siebolts, Claudia Wichenhauser, MD, Gopalakrishna Prashanth, MD MRCS, Dietger Niederwieser, MD, Astrid Monecke, MD

Blood (2014) 124 (21): 1836.

https://doi.org/10.1182/blood.V124.21.1836.1836

Published: 2014

Journal Articles

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Haifa Kathrin Al-Ali, MD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Julian Perez Ronco, MD MBA, Lynda M Foltz, MD FRCP

Blood (2014) 124 (21): 4583.

https://doi.org/10.1182/blood.V124.21.4583.4583

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

Occult Iron Deficiency Might be an Important Factor in MPN Patients with Myeloproliferative Neoplasms (MPN) Treated with Ruxolitinib. a Single Centre Experience

Eduardo E. Reynoso, MD

Blood (2014) 124 (21): 5564.

https://doi.org/10.1182/blood.V124.21.5564.5564

Published: 2014

Journal Articles

What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

Giovanni Barosi, MD, Valentina Poletto, Biol Sci, Elisa Bonetti, BS, Laura Villani, Biol Sci, Paolo Catarsi, PhD, Gianluca Viarengo, MD, Rita Campanelli, Biol. Sci, Margherita Massa, PhD, Vittorio Rosti, MD

Blood (2014) 124 (21): 3191.

https://doi.org/10.1182/blood.V124.21.3191.3191

Published: 2014

NARROW

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Leukemic Transformation of Post-Essential Thrombocythemia Myelofibrosis: A Unique Case Presenting with Double MPL and CALR Mutations

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood . 2013;122(25): 4047-4053 .

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Occult Iron Deficiency Might be an Important Factor in MPN Patients with Myeloproliferative Neoplasms (MPN) Treated with Ruxolitinib. a Single Centre Experience

What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only